Roivant dis­cussing sale of its Pfiz­er-part­nered UC drug to Roche for $7B, ac­cord­ing to re­port

Roivant is in dis­cus­sions with Roche to sell its ex­per­i­men­tal ul­cer­a­tive col­i­tis drug for sev­er­al bil­lion dol­lars, less than a year af­ter ac­quir­ing the pro­gram …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER